Adaptive Biotechnologies struck two non‑exclusive agreements with Pfizer granting the pharma access to Adaptive’s T‑cell receptor discovery platform and large‑scale TCR‑antigen mapping data. One deal covers identification of disease‑enriched TCRs for rheumatoid arthritis; the second provides Pfizer access to Adaptive’s TCR‑antigen datasets to train AI/ML models for R&D. Adaptive will receive an undisclosed upfront and may be eligible for development and commercial milestones that could total up to about $890 million, plus potential annual license fees. The companies said the collaborations aim to accelerate target discovery, therapeutic candidate selection, and biomarker development across immunology programs. The pacts underscore a broader industry shift toward licensing high‑value immune‑receptor data and algorithmic platforms to enable partner R&D and AI model training.